Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma
Mengmeng Liu, Tong Liu · 2026
Read Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma by Mengmeng Liu, Tong Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13279524.txt.
Description
Mengmeng Liu and Tong Liu published a 2026 cost-effectiveness analysis comparing two first-line drug combinations for inoperable liver cancer, judged from the viewpoint of payers in China. One pairing joins atezolizumab with bevacizumab; the other joins rivoceranib with camrelizumab. The authors built a three-state survival model from the two regimens' trial curves, extended with fits. Costs and quality-of-life weights came from published sources.
The atezolizumab combination was projected to cost about 109,556 dollars per patient against about 15,265 dollars for the rivoceranib combination. It also produced slightly fewer quality-adjusted life years, 1.47 against 1.59 in the model, a measure combining length and quality of life. A regimen that costs more while delivering less health is dominated. The authors conclude the rivoceranib pairing is the cost-effective choice for advanced disease in China. Such verdicts depend on local prices and trial populations, which readers should keep in view.
Catalog record
| CREATOR | Mengmeng Liu, Tong Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |